The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer
暂无分享,去创建一个
H. Beltran | J. Mosquera | H. Scher | M. Landers | S. Tagawa | D. Nanus | M. Kossai | R. Krupa | D. Marrinucci | R. Graf | N. Schreiber | A. Jendrisak | J. Louw | R. Dittamore
[1] Shuang Hou,et al. Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases , 2015, Cancer.
[2] P. Sternberg,et al. Erratum: The genome and transcriptome of the zoonotic hookworm Ancylostoma ceylanicum identify infection-specific gene families , 2015, Nature Genetics.
[3] Andrew Menzies,et al. Analysis of the Genetic Phylogeny of Multifocal Prostate Cancer Identifies Multiple Independent Clonal Expansions in Neoplastic and Morphologically Normal Prostate Tissue , 2015, Nature Genetics.
[4] M. Landers,et al. Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization , 2015, Journal of circulating biomarkers.
[5] A. Aparicio,et al. Neuroendocrine (small-cell) carcinomas: why they teach us essential lessons about prostate cancer. , 2014, Oncology.
[6] S. Tagawa. Neuroendocrine prostate cancer after hormonal therapy: knowing is half the battle. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] F Levi,et al. European cancer mortality predictions for the year 2014. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] M. Rubin,et al. Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation , 2014, The American journal of surgical pathology.
[9] T. Yap,et al. Circulating Tumor Cells: A Multifunctional Biomarker , 2014, Clinical Cancer Research.
[10] A. Armstrong,et al. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.
[11] M. Rubin,et al. Aggressive Variants of Castration-Resistant Prostate Cancer , 2014, Clinical Cancer Research.
[12] O. McCarty,et al. Physical biology in cancer. 2. The physical biology of circulating tumor cells. , 2014, American journal of physiology. Cell physiology.
[13] Wai Leong Tam,et al. The epigenetics of epithelial-mesenchymal plasticity in cancer , 2013, Nature Medicine.
[14] P. Thall,et al. Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer , 2013, Clinical Cancer Research.
[15] Mehmet Toner,et al. Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells , 2013, Science Translational Medicine.
[16] C. la Vecchia,et al. European cancer mortality predictions for the year 2014. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] Sridhar Ramaswamy,et al. Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition , 2013, Science.
[18] M. Rubin,et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] R. Weinberg,et al. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. , 2012, Seminars in cancer biology.
[20] Joshua M. Kunken,et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers , 2012, Physical biology.
[21] M. Gerstein,et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. , 2011, Cancer discovery.
[22] Andrew J Armstrong,et al. Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers , 2011, Molecular Cancer Research.
[23] S. Horvath,et al. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance , 2010, Nature Medicine.
[24] Peter Kuhn,et al. Cytomorphology of Circulating Colorectal Tumor Cells:A Small Case Series , 2010, Journal of oncology.
[25] Susan Halabi,et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Epstein,et al. Small Cell Carcinoma of the Prostate: A Morphologic and Immunohistochemical Study of 95 Cases , 2008, The American journal of surgical pathology.
[27] J. Nieva,et al. Case study of the morphologic variation of circulating tumor cells. , 2007, Human pathology.
[28] Peter Kuhn,et al. High speed detection of circulating tumor cells. , 2006, Biosensors & bioelectronics.
[29] P. Thall,et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] A. Jemal,et al. Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.
[31] M. Rubin,et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. , 2013, Neoplasia.
[32] L. Breiman. Random Forests , 2001, Machine Learning.
[33] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.